Novo Nordisk A/S vs PPG Industries, Inc. — how do they compare? Novo Nordisk A/S trades at $38.54 (market cap $165.31B), while PPG Industries, Inc. trades at $104.91 (market cap $23.44B). The key difference: Novo Nordisk A/S is far larger — about 7.1× PPG Industries, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and PPG Industries, Inc. for 68 Days on average.
| NVO | PPG | |
|---|---|---|
Market Cap | $165.31B | $23.44B |
Volume | 11,432,838 | 2,064,777 |
Sector | Health | Basic Materials |
52-Week High | $63.98 | $131.56 |
52-Week Low | $35.29 | $94.34 |
Typical Hold Time | 116 Days | 68 Days |
Enterprise Value | $179.56B | $29.31B |
Dividend Yield | 4.71% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
PPG trades at $105.08, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q2 2026 EPS miss of $2.23 vs. $2.25 expected, though Q1 2026 beat expectations. Fundamentals show a P/E of 15.13, net income margin of 9.57%, and strong cash flow from operations of $1.94B in 2025. Recent news highlights margin pressures in the Automotive Refinish segment but innovation efforts in marine coatings.
The outlook is cautiously optimistic, with a consensus price target of $130 implying 24% upside, supported by 55% analyst buy ratings. Risks include segment-specific weakness and macroeconomic headwinds, but valuation remains reasonable with solid profitability. The stock offers a dividend yield from its upcoming $0.74 payout, appealing for income-focused investors amid ongoing cost management initiatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →